# MOTS-c

> Source: https://peptidestogo.com/peptides/mots-c/
> Last updated November 2, 2026 · PeptidesToGo Editorial Team · Educational, not medical advice

Mitochondrial-derived peptide

**Status:** Not FDA-approved · compounded · Prescription only

**How it is delivered:** Injection — two to three times a week.

MOTS-c is a 16-amino-acid peptide encoded inside the mitochondrial genome — specifically, in a short sequence nested within the 12S ribosomal RNA gene. That address is unusual. Nearly every hormone and signaling peptide in the body comes from nuclear DNA. MOTS-c comes from the mitochondria themselves, which means the organelles we’ve long thought of as cellular power plants also operate as endocrine organs with their own signaling vocabulary.

The peptide activates AMPK, the cellular energy sensor that turns on when ATP runs low. The downstream cascade resembles exercise or caloric restriction: glucose uptake improves, fat oxidation rises, mitochondrial biogenesis turns on. Under metabolic stress, MOTS-c also translocates into the nucleus and regulates antioxidant response genes — a mitochondrial-encoded peptide reaching into the nucleus is the only documented example of this kind of bidirectional organelle communication.

> “MOTS-c is what happens when mitochondria talk back — not just burning fuel, but sending signals that reshape how the whole cell handles energy.”

Most of the efficacy data comes from rodent work. In mice, MOTS-c improved glucose tolerance, prevented diet-induced obesity, and increased exercise capacity. In humans, the peptide rises sharply during exercise and correlates with anaerobic muscle performance. What’s missing is the interventional trial that would tell us whether injecting MOTS-c into a person produces the metabolic or performance changes the animal models suggest. The full study breakdown lives on our PeptideWellness deep-dive.

Last updated November 2, 2026 · PeptidesToGo Editorial Team ·
[Educational, not medical advice](https://peptidestogo.com/legal/medical-disclaimer/)

## Who it's for (or who should avoid)

### What it's aimed at

MOTS-c protocols are most commonly prescribed for:

- **Metabolic support** — patients with insulin resistance, prediabetes, or metabolic syndrome looking for adjunctive support alongside lifestyle change
- **Exercise recovery** — athletes managing training load and looking to improve recovery between sessions
- **Age-related metabolic decline** — older adults with declining glucose handling or mitochondrial function
- **Body composition goals** — prescribed compounded for fat oxidation and lean mass preservation during caloric restriction

### Who should avoid it

- Anyone with an active or recent cancer — AMPK activation has complex effects on tumor metabolism; oncologist sign-off is the right step
- People who are pregnant, breastfeeding, or planning a pregnancy in the near term — no controlled human safety data
- Athletes subject to WADA testing — MOTS-c is on the Prohibited List as an AMPK activator
- Patients unwilling to undergo baseline metabolic labs (fasting glucose, HbA1c, lipids) — the peptide affects glucose handling and should be monitored

> Your own MOTS-c rises when you exercise. Whether injecting it produces the same thing is the question the research has not answered yet.

Human evidence is observational: lower circulating MOTS-c shows up in T2D, obesity, chronic kidney disease, and older adults. Whether raising it exogenously produces the reverse effect is the question trials haven’t yet answered.

## Route, dose and course

**Used for:** Metabolic and mitochondrial protocols

**How it’s taken:** Subcutaneous injection. It does not cross the blood–brain barrier by this route, so cognitive claims do not follow from standard dosing.

**Doses sellers list:** Rx Peps Direct lists 0.4 mg per injection, or 2 mg in its high-dose vial. It does not say how often. — No dose is approved for MOTS-c. We searched the sellers' own pages so you don't have to; the figures are theirs, not a recommendation. Your prescriber sets the dose. Where these figures come from: Rx Peps Direct peptide list (checked Oct 16, 2026)

**Cycle:** Not published — None of the sellers we checked publishes a cycle.

**Legal status:** Not FDA-approved and not on the 503A bulks list. Since October 28, 2026, HHS has said it will not act against licensed pharmacies that compound it for a named patient as a single ingredient, by subcutaneous or intramuscular injection, under the conditions of its enforcement-discretion policy. Blends and research-use-only products are outside it.

**What it costs:** About $200 a month — From the sellers' own pages on November 4, 2026; some sell it per vial or unit instead. Each figure, with what it leaves out, is in the table under “Can I actually get it?”. Human pharmacokinetics have never been established, so no figure maps onto a standard protocol.

MOTS-c is most commonly prescribed as a subcutaneous injection. The peptide doesn’t cross the blood-brain barrier via systemic administration, so claims about cognitive effects from standard dosing don’t square with the route-of-administration data.

What sellers publish (we checked their own pages on 16 October 2026):

- **Dose:** [Rx Peps Direct](https://www.rxpepsdirect.com/peptides) lists 0.4 mg per injection, or 2 mg in its high-dose vial, and does not say how often. No dose is approved for MOTS-c
- **Cycling:** none of the sellers we checked publishes one
- **Stacking:** [Rx Peps Direct](https://www.rxpepsdirect.com/peptides) sells MOTS-c blended with SS-31 and tesamorelin in one vial

Reconstitution typically uses bacteriostatic water. Human pharmacokinetics (half-life, clearance, absorption) haven’t been published, so no human dose rests on measured data. This is something to set with your prescriber, not a self-directed protocol.

## No measured timeline

No human trial has measured how soon MOTS-c works or how long any effect lasts, and we found no source we trust for a week-by-week picture, so we do not draw one. Agree with your prescriber what you will measure and when you will check it.

## Available · from about $200/mo

Every headline price in this market excludes something. These are normalized to a
 calendar month, cheapest first, with the exclusion spelled out — the published figure
 is the footnote under it.

| Provider | From, per month | What that figure excludes | Coverage | Their own site |
| --- | --- | --- | --- | --- |
| [Live Vital](https://peptidestogo.com/providers/live-vital/) — Physician-led, monthly pricing, Draper UT | $200 (read 2026-11-04) | The dose the figure buys, which is not published; sold as a 2-month subscription, $399 every 2 months. | All 50, stated | [Go to site ↗](https://livevital.io/) |
| [Defy Medical](https://peptidestogo.com/providers/defy-medical/) — Tampa clinic, physician-led | No price for this compound | Peptides are priced per vial rather than per month, and neither the consultation nor the lab work that has to precede it is priced anywhere on the site. | Not published | [Go to site ↗](https://www.defymedical.com/) |
| PeRx — Peptide-only telehealth, Wellness MD Group PC | No price for this compound | The only peptide figure on the site is a floor for the whole menu — treatment plans "starting at $199" — so there is no price for any individual compound. The provider review is included; there is no separate consultation fee. | All 50, stated | [Go to site ↗](https://www.perxpeptides.com/) |
| [RxPepsDirect](https://peptidestogo.com/providers/rxpepsdirect/) — Per-vial prices, 503A pharmacy in Texas | $80 per vial (read 2026-11-04) | The $39 telehealth visit, charged per order. | A named list | [Go to site ↗](https://rxpepsdirect.com/) |

### Will it work where you live?

Most sellers claim all fifty states or publish nothing about coverage; a few name
 the states they serve or the ones they exclude, and the Coverage column says which.
 Either way it is the seller's own claim, so we can't filter this list by state
 without inventing a fact. What we can tell you is which state-level rules decide
 access: telehealth rules, non-resident pharmacy licensing, and who is allowed to
 prescribe.

[What shapes access in your state →](https://peptidestogo.com/tools/state-checker/)

### Prices and providers change. We keep track.

## Questions we get about MOTS-c

### Is MOTS-c FDA-approved?

No — it's not an FDA-approved drug and isn't sold at retail pharmacies. There is no approved label for it to be prescribed off; licensed clinicians prescribe it and compounding pharmacies prepare it. MOTS-c is not on the 503A Bulks List of permitted compoundable substances. On July 23, 2026 the FDA's Pharmacy Compounding Advisory Committee reviewed it for obesity and osteoporosis: the agency's own reviewers proposed leaving it off, and the committee voted 7–5–2 to recommend adding it. That recommendation does not change the rule by itself — the FDA has to act on it — so confirm current availability with your provider.

### Is it legal?

Compounding it on a prescription is now tolerated, under conditions, though it is still on no list that authorises it. Section 503A lets a pharmacy compound only from an ingredient of an FDA-approved drug, a substance with a USP monograph or one on the FDA's 503A bulks list, and MOTS-c is none of these. On October 28, 2026, HHS said it will not take action against State-licensed pharmacies and licensed physicians that compound MOTS-c for a named patient while the FDA decides whether to list it. The conditions: MOTS-c is the only active ingredient, the route is subcutaneous or intramuscular injection, the bulk substance comes from an FDA-registered manufacturer named on a certificate of analysis, and serious side effects are reported to the FDA. HHS can withdraw the policy. A blend that mixes MOTS-c with other peptides is outside it, and buying from "research chemical" sellers without a prescription is still not a lawful supply route for human use. Since November 2, 2026, LegitScript, the certifier whose seal many telehealth sites show, no longer refuses certification to sellers whose MOTS-c meets these conditions; that seal is not FDA approval.

### Are there side effects?

The honest answer: we don't have formal human safety data. The FDA has stated it lacks sufficient information to characterize the safety profile. Preclinical work in rodents showed no overt toxicity at therapeutic doses. Theoretical concerns include immunogenicity (antibody formation against the peptide) and impurity-related risks in compounded products. Providers typically advise against use in active or recent cancer, pregnancy, breastfeeding, or without baseline metabolic labs.

### Can I take it with my current medications?

No formal drug-interaction study has been published, and MOTS-c's half-life in humans is not even established — so there is no basis for saying interactions are unlikely. Because it activates AMPK and affects glucose handling, discuss it with your provider if you're on diabetes medications, metformin, or other metabolic drugs. Always disclose your full medication and supplement list.

### How much does it cost?

In the price table on this page, the monthly figure is about $200, read on November 4, 2026. Some sellers price it per vial or unit instead, shown in the same table. Neither a vial price nor a monthly one tells you what a course costs, because human pharmacokinetics have never been established, so there is no standard protocol to price against. Providers extrapolate dosing from rodent work, and what one calls a month's supply another does not. It is also one of the seven peptides an FDA advisory committee reviewed in July 2026, with no agency decision yet. Get the protocol and its cost in writing together. Insurance does not cover it.

We publish no medical reviewer by design. Every claim on this page traces to a
 source we hold on file, and the reviewed write-up with those citations lives on our
 hub.
[Read the full research on PeptideWellness ↗](https://peptidewellnessusa.com/peptides/mots-c/)

## Related peptides